VRNA Verona Pharma plc

5.56
0  0%
Previous Close 5.56
Open
Price To Book 1
Market Cap 73,202,009
Shares 13,165,829
Volume 0
Short Ratio
Av. Daily Volume 4,417

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data released March 2, 2018.
RPL554
Cystic fibrosis
Phase 2 trial did not meet primary endpoint - January 14, 2019.
RPL554
COPD
Phase 2 data due 3Q 2019.
RPL554 DPI formulation
Maintenance treatment of COPD
Phase 2b data due 4Q 2019.
Ensifentrine (RPL554) and tiotropium
Chronic obstructive pulmonary disease (COPD)
Phase 2 initiation announced June 4, 2019. Data from first part of trial due 2H 2019. Final data 1Q 2020.
Ensifentrine (RPL554) - Metered Dose Inhaler
Maintenance treatment of COPD

Latest News

  1. Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
  2. Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
  3. Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
  4. Result of AGM
  5. Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
  6. Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
  7. Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
  8. Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
  9. Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
  10. Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
  11. Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
  12. Grant of Options and RSUs and PDMR Dealings
  13. Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
  14. PDMR Dealing
  15. 2018 Annual Report and Accounts and Notice of AGM 
  16. Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director